OTC Watch

All stocks / IDXG

INTERPACE BIOSCIENCES, INC. IDXG

Interpace Biosciences (IDXG): shares outstanding up 33% in a year and the latest annual figures in plain language. Each fact links to its SEC filing.

Dilution OTCIDNew Jersey, USA
Live quote on OTC Markets

Market listing

Full name
INTERPACE BIOSCIENCES INC
Market tier
OTC Pink Current
Trading status
Active
Last trade
Nov 16
Website
www.interpacediagnostics.com
Source: Stockwatch, 2026-11-17

News headlines

Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results
2026-11-16 16:01 · News Release
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
2026-10-14 20:29 · News Release
Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
2026-08-26 16:05 · News Release
Interpace Biosciences Announces Second Quarter 2026 Financial and Business Results
2026-08-10 16:35 · News Release
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
2026-05-12 16:06 · News Release
Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results
2026-03-30 16:01 · News Release
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
2026-01-20 09:00 · News Release
Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners
2025-12-03 12:12 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$38,728,000
Net income
$24,575,000
What it means

It earned more than it spent

Steady

After all costs, the company kept $24.6 million as profit in the year.

The report says
Cash and cash equivalents
$2,505,000
Net cash from operating activities
$5,831,000
What it means

The business brings in cash

Steady

Day-to-day business added $5.8 million in cash over the year. It had $2.5 million in the bank.

The report says
Total assets
$33,838,000
Total liabilities
$11,475,000
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $33.8 million. Its debts and unpaid bills add up to $11.5 million. That is about $0.34 owed for every $1 owned.

What this adds up to

0 of 3 checks show strain. These are facts from the company's own reports, not a recommendation.

Signals

Dilution2026-11-06

Shares outstanding rose from 4,428,539 (2025-11-07) to 5,901,964 (2026-11-06), up 33%.

Rule: Shares outstanding up 20% or more in 12 months. Source record

Shares outstanding

Source: SEC filings
2026-03-20
27.7M
2026-03-31
27.7M
2026-04-15
27.7M
2026-05-01
27.7M
2026-06-30
27.7M
2026-07-31
27.7M
2026-09-30
5.9M
2026-11-06
5.9M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-Q10-Q
2026-11-05 8-A12B8-A12B
2026-11-05 CERT
2026-10-30 S-1/AS-1/A
2026-10-15 8-K8-K
2026-10-15 FWPFWP
2026-10-01 S-1/AS-1/A
2026-09-25 S-1S-1
2026-09-17 S-8S-8
2026-08-27 8-K8-K
2026-08-26 8-K/A8-K/A
2026-08-21 8-K8-K

Common questions about IDXG

Does IDXG file reports with the SEC?

Yes. Interpace Biosciences files with the SEC under company number 0001054102. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many IDXG shares are outstanding?

5,901,964 shares as of 2026-11-06, as reported to the SEC. That is up 33% from 4,428,539 on 2025-11-07.

Source record

Has IDXG filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Interpace Biosciences?

Officers named in its insider filings: Thomas W. Burnell (CEO, President & Chairman) and Christopher McCarthy (CFO & COO).

Source record

Is Interpace Biosciences making money?

After all costs, the company kept $24.6 million as profit in the year. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record